Keywords
South America
Biological Treatment
DAS28
How to Cite
Abstract
Introduction: In patients with rheumatoid arthritis (RA), disease activity is often determined through the DAS28 index. Subjective components included in the index can be influenced by non-inflammatory factors, and overestimate disease activity. The DAS28 index and its subjective components have not been extensively studied in South Americans.
Objectives: Analyze the subjective components of DAS28 as well as clinical and serological variables related to it in South American patients with rheumatoid arthritis treated with biologics.
Methods: Retrospective longitudinal analysis of patients from BIOBADAGUAY registry. The formula for the subjective component of DAS28 was determined. DAS28 and its components were analyzed for both populations at treatment initiation, and 52 week follow up, and associations with clinical and serological variables were evaluated.
Results: The Paraguayan patients had lower mean age, number of comorbidities and less smokers. They were also found to have lower DAS28, sDAS28, PGH and TJC. Country of origin, number of comorbidities, BMI, smoking history and methotrexate use were associated to subjective components of DAS28 at treatment initiation. Changes in sDAS28 at week 52 were highly determined by its initial value. No association was found with objective variables (CRP, ESR, number of treatments.)
Conclusions: Variables other than inflammatory disease activity can influence sDAS28 and DAS28 of South American patients. Their management must be individualized and not be based solely on DAS28 value.
References
(1) Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69(4):638-43.
(2) Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
(3) Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, NJ). 2016;68(1):1-26.
(4) Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15.
(5) Buzatu C, Moots RJ. Measuring disease activity and response to treatment in rheumatoid arthritis. Expert Review of Clinical Immunology. 2019;15(2):135–45.
(6) Van Riel PLCM. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-65-74.
(7) Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis Rheum. 1995;38(1):44-8.
(8) Hammer HB, Michelsen B, Provan SA, Sexton J, Lampa J, Uhlig T, et al. Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. Arthritis Care Res (Hoboken). 2020;72(1):27-35.
(9) Salaffi F, Di Carlo M, Carotti M, Sarzi-Puttini P. The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. Rheumatol Int. 2018;38(10):1911-8.
(10) McWilliams DF, Kiely PDW, Young A, Joharatnam N, Wilson D, Walsh DA. Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoidarthritis. BMC Rheumatol [Internet]. 2018 Mar 23 [cited 2020 Jan 22];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390559/
(11) Ten Klooster PM, de Graaf N, Vonkeman HE. Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study. Arthritis Res Ther. 2019 Nov 29;21(1):257.
(12) Yazici Y, Kautiainen H, Sokka T. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol. 2007;34(2):311-5.
(13) Barton J, Trupin L, Schillinger D, Gansky S, Tonner C, Margaretten M, et al. Racial and Ethnic Disparities in Disease Activity and Function among Persons with Rheumatoid Arthritis from University Affiliated Clinics. Arthritis Care Res (Hoboken). 2011;63(9):1238-46.
(14) Karpouzas GA, Dolatabadi S, Moran R, Li N, Nicassio PM, Weisman MH. Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(9):1274-81.
(15) McWilliams DF, Zhang W, Mansell JS, Kiely PDW, Young A, Walsh DA. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res (Hoboken). 2012;
(10):1505–13.
(16) Son KM, Lee SY, Seo YI, Choi J-E, Kim HA. Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis. Clin Rheumatol. 2017;36(6):1221-7.
(17) Putrik P, Ramiro S, Hifinger M, Keszei AP, Hmamouchi I, Dougados M, et al. In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Ann Rheum Dis. 2016;75(4):715-20.
(18) Jurgens MS, Overman CL, Jacobs JWG, Geenen R, Cuppen BVJ, Marijnissen ACA, et al. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015;67(7):923-8.
(19) Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J Rheumatol. 2019;46(6):564-71.
(20) Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C. Impact of Obesity on Remission and Disease Activity in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2017;69(2):157-65.
(21) Derdemezis CS, Voulgari PV, Drosos AA, Kiortsis DN. Obesity, adipose tissue and rheumatoid arthritis: coincidence or more complex relationship? Clin Exp Rheumatol. 2011;29(4):712-27.
(22) Castillo-Hernandez J, Maldonado-Cervantes MI, Reyes JP, Patiño-Marin N, Maldonado-Cervantes E, Solorzano-Rodriguez C, et al. Obesity is the main determinant of insulin resistance more than the circulating pro-inflammatory cytokines levels in rheumatoid arthritis patients. Rev Bras Reumatol Engl Ed. 2017;57(4):320-9.
(23) Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and rheumatoid arthritis. Int J Mol Sci. 2014;15(12):22279-95.
(24) Roos K, Martinsson K, Ziegelasch M, Sommarin Y, Svärd A, Skogh T, et al. Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking. Arthritis Res Ther. 2016;23;18(1):119.
(25) Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group. Predictors, demographics and frequency of sustained remission and low disease activity in antitumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2019 01;58(12):2162-9.
(26) Gianfrancesco MA, Trupin L, Shiboski S, van der Laan M, Graf J, Imboden J, et al. Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates. J Rheumatol. 2019;46(4):370-5.
(27) Verstappen SMM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, et al. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care Res (Hoboken). 2015;67(12):1637-45.
(28) Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. The Journal of Rheumatology. 2007;34(12):2382-7.
(29) Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, Mantilla RD, Castellanos-de la Hoz J, Bernal-Macías S, et al. Gender differences in Latin-American patients with rheumatoid arthritis. Gend Med. 2012;9(6):490-510.e5.